The Role of Mesenchymal Stem Cells in Cancer Immunotherapy-Reference-Cited by-同舟云学术

The Role of Mesenchymal Stem Cells in Cancer Immunotherapy

Published:2023-11 Issue:8 Volume:18 Page:1056-1068
ISSN:1574-888X
Container-title:Current Stem Cell Research & Therapy
language:en
Short-container-title:CSCR

Author:

Zhao Yueshui¹²,Zhong Xianmei¹²³,Du Fukuan¹²,Wu Xu¹²,Li Mingxing¹²,Wen Qinglian⁴,Shen Jing¹²,Chen Yu¹²,Zhang Xinyi⁵,Yang Zhongming⁶,Deng Ying⁷,Liu Xiang⁷,Zou Chang⁸,Du Yu⁷,Xiao Zhangang¹⁹

Affiliation:

1. Laboratory of Molecular Pharmacology, School of Pharmacy, Department of Pharmacology, Southwest Medical University, Luzhou, Sichuan, China

2. South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China

3. Department of Pharmacy, People’s Hospital of Nanbu County, Nanchong, Sichuan China

4. Department of Oncology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

5. School of Data Science, The Chinese University of Hong Kong, Shenzhen, China

6. Department of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China

7. Medical Cosmetology Center, Affiliated of Traditional Chinese Medicine, Southwest Medical University, Luzhou, Sichuan, PR China

8. Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, PR China

9. Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan, China

Abstract

Abstract: Mesenchymal stem cells (MSCs) are getting attention in the field of cancer immunotherapy. The main effects of MSCs on tumors are homing and regulation of inflammatory and immune responses. Indeed, cancer immunotherapy has become a promising treatment and MSCs play a potential role in regulating the efficacy of immunotherapy. In addition, MSCs are an ideal carrier for immunomodulatory protein transmission. As such MSCs combined with immunotherapy drugs could act synergistically against tumors, throwing a great impact on cancer therapy. And MSCs may have potential in the treatment of cytokine storm or cytokine release syndrome (CRS). It is assumed that MSCs can form chimeric antigen receptor MSCs (CAR-MSCs). Whether CAR-MSCs can provide a new idea of cancer immunotherapy is unknown. It is a prime time to review the latest progress of MSCs in cancer immunotherapy, in order to clarify to fully understand the role of MSCs in cancer therapy in clinical practice.

Funder

National Natural Science Foundation of China

Sichuan Science and Technology Project

Publisher

Bentham Science Publishers Ltd.

Subject

General Medicine,Medicine (miscellaneous)

Reference123 articles.

1. Porada C.; Zanjani E.; Almeida-Porada G.; Adult mesenchymal stem cells: A pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006,1(3),365-369

2. Simões B.P.; Tone L.G.; Zago M.A.; Figueiredo M.S.; Splenic function in acute leukemia. Acta Haematol 1995,94(3),123-127

3. Kennedy L.B.; Salama A.K.S.; A review of cancer immunotherapy toxicity. CA Cancer J Clin 2020,70(2),86-104

4. Meng M.Y.; Li L.; Wang W.J.; Assessment of tumor promoting effects of amniotic and umbilical cord mesenchymal stem cells in vitro and in vivo. J Cancer Res Clin Oncol 2019,145(5),1133-1146

5. Li A.; Guo F.; Pan Q.; Mesenchymal stem cell therapy: Hope for patients with systemic lupus erythematosus. Front Immunol 2021,12,728190